New imaging agent radiocaine enters human safety testing
NCT ID NCT07081217
First seen Jun 27, 2026 · Last updated Aug 28, 2026 · Updated 2 times
Summary
This early-phase study tests the safety and radiation of Radiocaine, a new radioactive tracer for PET scans. Six healthy adult volunteers will receive an injection and be monitored for side effects and radiation exposure. The goal is to see if Radiocaine can safely light up nerve activity in future imaging studies.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Radiocaine (a radioactive tracer for PET scans)
- What this could lead to
- If successful, this could lead to a new way to see nerve activity in the body using a PET scan.
- What could go wrong
- This is a very early, tiny trial (6 people) just checking safety and radiation. It may not lead to a useful diagnostic tool.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Early phase 1
The earliest testing in people: a first look at safety, in a very small group.
- Participants
-
About 6 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2025
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * 18 years and older * Able to provide written consent * Willing and able to undergo ECG, imaging, blood sampling, and complete self-assessment rating scales at the specified time points * Willing and able to participate in all imaging procedures and complete the self-assessment rating scales at the specified time points Exclusion Criteria: * Body mass index (BMI) of 32 or greater, weight \>300 lbs * Diagnosis of severe depression/anxiety (PROMIS score \> 95%) or suicidal ideation * History of opioid abuse or opioid use disorder * History of seizures or epilepsy * History of major Axis I or Axis II psychiatric disorder that might, in the opinion of the investigator, make it difficult for the subject to complete all the procedures (e.g. obsessive-compulsive disorder, bipolar disorder, schizophrenia, or schizoaffective disorder) * History of cardiac arrhythmia * History of major orthopedic surgery within the last 12 months * Recent history (previous 6 months) of sodium channel blocker use, including, but not limited to: carbamazepine, lamotrigine, lidocaine, phenytoin, propranolol, or valproate * Any significant systemic illness or medical condition that could lead to difficulty complying with the study protocol * Creatinine clearance (calculated using the Cockcroft-Gault formula or measured) \< 60 mL/min or serum creatinine \>1.5 x ULN * QTcF \>470 msec for females and QTcF \>450 msec for males on screening ECG * MRI-incompatible implants, large tattoos, previous shrapnel injury * Pregnancy or lactating * History of contact sport participation, such as football, hockey, or rugby * Known claustrophobia related to MR or PET-MRI scanners * Recent blood donation/draw of \>1 unit (previous 4 weeks) * History of hypersensitivity to local anesthetics of the amide type * Family or personal history of familial malignant hyperthermia
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Healthy subjects are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The study's own enquiry address
This study publishes an address for enquiries. See it below .
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Stanford University School of Medicine
RECRUITINGStanford, California, 94305, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple reaching exercise strengthen ankles and cut injury risk?
- Urine chemistry may hold key to safer dosing for brain drug
- Could a skin patch replace IV sedation? early test in healthy adults
- Can a common amino acid help your body build more protein?
- Fine-Mist inhalers aim to reach deep lungs in COPD
- Can antibodies enter the bloodstream via the colon?